Introduction. Elevated plasma matrix metalloproteinase-9 (MMP-9) levels have been suggested to precede the development of microalbuminuria. As angiotensin-converting enzyme (ACE) inhibitors effectively reduce urinary albumin excretion (UAE), in the present study we have investigated the potential association of plasma MMP-9 levels with UAE and treatment effects of ACE-inhibition. Material and methods. In a placebo-controlled
randomised trial we determined plasma MMP-9 levels at baseline and after three months of randomisation to either placebo (n=202) or fosinopril (20 mg/day, n=204) treatment.
Results. Baseline plasma MMP-9 levels were not related to baseline UAE (r=-0.008, p=0.871).Three months of fosinopril treatment effectively reduced UAE compared to placebo treatment (-10.4±2.4 vs. 1.8±1.3 mg/24 hours, p<0.001, respectively). However, fosinopril treatment failed to significantly change plasma MMP-9 levels compared to placebo (-0.47±7.68 vs. 0.06±9.20, p=0.646, respectively) . In addition, the change in UAE was not related with change in MMP-9 levels.
Conclusion. The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels.
Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A.Albuminuria reflects widespread vascular damage. The Steno hypothesis . Diabetologia1989;32:219-26.
2.
Yuyun MF, Khaw KT, Luben R. et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol2004;159:284-93.
3.
Hillege HL, Fidler V., Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation2002;106:1777-82.
4.
Gerstein HC, Mann JF, Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA2001;286:421-6.
5.
Bigazzi R., Bianchi S., Baldari D., Campese VMMicroalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens1998;16:1325-33.
6.
Jensen JS, Feldt-Rasmussen B., Borch-Johnsen K., Clausen P., Appleyard M., Jensen G.Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens1997;11:727-32.
7.
Allen KV, Walker JDMicroalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care2003;26:2389-91.
8.
Romundstad S. , Holmen J., Kvenild K., Hallan H., Ellekjaer H.Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis2003;42:466-73.
9.
Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., Schroll M., Jensen JSUrinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol1999;19:1992-7.
10.
Kannel WB, Stampfer MJ, Castelli WP, Verter J.The prognostic significance of proteinuria: the Framingham study. Am Heart J1984;108:1347-52.
11.
Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria . Circulation2004;110:2809-16.
12.
Parving HH, Hommel E., Smidt UMProtection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ1988;297:1086-91.
13.
Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M.Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients . Ann Intern Med1993;118:577-81. 14. Effects of ramipril on cardiovascular and microvascular
14.
outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet2000;355:253-9. 15. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing
15.
microalbuminuria in type 2 diabetes. N Engl J O Med2004;351:1941-51.
16.
Viberti G., Mogensen CE, Groop LC, Pauls JFEffect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA1994;271:275-9. converting enzyme inhibitors and progression of nondiabetic
17.
Jafar TH, Schmid CH, Landa M. et al. Angiotensinconverting progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med2001;135:73-87.
18.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349:1857-63.
19.
van de Wal RM, Gansevoort RT, van der Harst P. et al. Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients. Hypertension2006;48:870-6.
20.
van de Wal RM, Plokker HW, Lok DJ et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition . Int J Cardiol2006 ;106:367-72.
21.
Tsilibary ECMicrovascular basement membranes in diabetes mellitus. J Pathol2003;200:537-46.
22.
Ebihara I., Nakamura T., Shimada N., Koide H.Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis1998;32:544-50.
23.
Diercks GF, Janssen WM, van Boven AJ et al. Rationale, design M ,and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol2000;86:635-8.
24.
Sundstrom J. , Evans JC, Benjamin EJ et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study . Circulation2004;109:2850-6.
25.
Boffa JJ, Lu Y., Placier S., Stefanski A., Dussaule JC, Chatziantoniou C.Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol2003;14:1132-44.
26.
Tashiro K., Koyanagi I., Ohara I. et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal2004;18:206-10.
